WO2003097614A2 - Process for the preparation of rosuvastatin - Google Patents

Process for the preparation of rosuvastatin Download PDF

Info

Publication number
WO2003097614A2
WO2003097614A2 PCT/IB2003/001946 IB0301946W WO03097614A2 WO 2003097614 A2 WO2003097614 A2 WO 2003097614A2 IB 0301946 W IB0301946 W IB 0301946W WO 03097614 A2 WO03097614 A2 WO 03097614A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
structural formula
give
derivative
process according
Prior art date
Application number
PCT/IB2003/001946
Other languages
French (fr)
Other versions
WO2003097614A3 (en
Inventor
Yatendra Kumar
Shantanu De
Mohammad Rafeeq
Hashim Nizar Poovanathil Nagoor Meeran
Swargam Sathyanarayana
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Priority to AU2003228010A priority Critical patent/AU2003228010A1/en
Priority to US10/515,361 priority patent/US20050222415A1/en
Priority to BR0311195-4A priority patent/BR0311195A/en
Priority to EA200401533A priority patent/EA200401533A1/en
Priority to EP03725478A priority patent/EP1585736A2/en
Publication of WO2003097614A2 publication Critical patent/WO2003097614A2/en
Publication of WO2003097614A3 publication Critical patent/WO2003097614A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Definitions

  • the present invention relates to a cost effective and industrially advantageous process for the preparation of 4-4(fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsul ⁇ honylammo)-5-pyrimidinecarboxaldehyde, referred to here as pyrimidine aldehyde of structural Formula I
  • rosuvastatin is (+)-(3R, 5S)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N- methyl-N-methylsulphonylamino) pyrimidin-5-yl]-3, 5-dihydroxy-6(E)-heptenoic acid calcium salt (2:1) having the structural Formula II
  • Rosuvastatin is an antihypercholesterolemic drug used in the treatment of atherosclerosis.
  • Hypercholesterolemia is now well recognized as a primary risk in coronary heart disease.
  • Clinical studies with lipid lowering agents have established that decreasing elevated serum cholesterol level reduces the incidence of cardiovascular mortality.
  • rosuvastatin calcium has consistently shown greater potency than other currently marketed statins (atorvastatin, simvastatin and pravastatm) in preclinical and clinical testing.
  • Rosuvastatin and a process for its preparation are disclosed in U.S. Patent No. 5,260,440.
  • the process disclosed therein involves four distinct chemical steps: (1) condensation of methyl (3R)-3-(rert-butyldimethylsilyloxy)-5-oxo-6- triphenylphosphoranylidene hexanate, referred to here as phosphorane with 4-(4- fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)-5- pyrimidinecarboxaldehyde, referred to here as pyrimidine aldehyde; (2) deprotection of the 3-hydroxyl group to give a keto alcohol; (3) reduction of 5-oxo to get a chiral dihydroxy heptenate; and (4) hydrolysis of the dihydroxy heptenate and conversion to hemicalcium salt.
  • the generation of the pyrimidine aldehyde requires eight synthetic steps and involves the use of expensive reagents and toxic solvents.
  • the process results in the formation of several side products at various intermediate steps thus necessitating purification at the cost of low yields.
  • the process is both uneconomical and time consuming, hence not suitable for commercial production.
  • the present invention provides a process for the preparation of rosuvastatin, its salts, esters, or the corresponding cyclized lactone form.
  • the process provides obvious benefits with respect to economics and convenience to operate on a commercial scale. Detailed Description of the Invention
  • XVT comprising: a. condensing 4-fluorobenzaldehyde of structural Formula VIII with a compound of structural Formula XVII, wherein Ri is independently C 2 -6 alkyl, C ⁇ - 6 cycloalkyl or aralkyl, to give an olefin of structural Formula xv ⁇ i, b. reacting the olefin with isothiourea of structural Formula IX, wherein R 2 is independently C 2 -e alkyl, . 6 cycloalkyl or aralkyl, to give a cyclized dihydropyrimidine derivative of structural Formula XIX, c.
  • the condensation at step a) can be carried out in a suitable solvent, for example . hexane, heptane, cycloheptane, cyclohexane, and mixture(s) thereof at a reflux temperature in the presence of piperidine and glacial acetic acid.
  • a suitable solvent for example . hexane, heptane, cycloheptane, cyclohexane, and mixture(s) thereof at a reflux temperature in the presence of piperidine and glacial acetic acid.
  • the cychzation at step b) can be carried out in a suitable solvent, for example N, N-dimethylacetamide, N, N-dimethylformamide, dimethylsulphoxide, acetonitrile, and mixture(s) thereof in the presence of molecular sieves.
  • a suitable solvent for example N, N-dimethylacetamide, N, N-dimethylformamide, dimethylsulphoxide, acetonitrile, and mixture(s) thereof in the presence of molecular sieves.
  • the aromatization at step c) can be carried out with ⁇ -manganese dioxide in the presence of a solvent, for example dichloromethane, chloroform, toluene, benzene, ethyl acetate, and mixture(s) thereof.
  • a solvent for example dichloromethane, chloroform, toluene, benzene, ethyl acetate, and mixture(s) thereof.
  • the oxidation reaction at step d) can be carried out with peracetic acid or hydrogen peroxide in a solvent, for example dichloromethane, chloroform, toluene, benzene, ethyl acetate, and mixture(s) thereof.
  • the methylamination at step e) can be carried out with methylamine in a solvent, for example toluene, methylene chloride, tetrahydrofuran, dioxane, and mixture(s) thereof.
  • a solvent for example toluene, methylene chloride, tetrahydrofuran, dioxane, and mixture(s) thereof.
  • the methanesulphonation at step f) can be carried out in the presence of n- butyllithium.
  • the selective oxidation of the alcoholic compound at step h) can be carried out with ⁇ -manganese dioxide in a suitable solvent, for example methylene chloride, tetrahydrofuran, dioxane, and mixture(s) thereof to give a pyrimidine aldehyde of structural Formula I.
  • a suitable solvent for example methylene chloride, tetrahydrofuran, dioxane, and mixture(s) thereof to give a pyrimidine aldehyde of structural Formula I.
  • reaction (a) to (h) of Scheme I can be performed and worked up in a manner conventional for the type of reaction involved.
  • the reaction parameters such as concentration, reaction duration, temperature, molar ratios of reagents can be chosen according to principles well established in the art.
  • a process for the preparation of cyclized dihydropyrimidine derivative of structural Formula XIX comprising reaction of an olefin of structural Formula XVIII with isothiourea of structural Formula IX, wherein R 2 is independently C 2 - 6 alkyl, Ci- ⁇ cycloalkyl or aralkyl.
  • a process for the preparation of a pyrimidine compound of structural Formula XX comprising aromatization of the dihydropyrimidine derivative of structural Formula XIX with ⁇ -manganese dioxide.
  • a process for the preparation of a sulphonyl derivative of structural Formula XXI comprising oxidation of the pyrimidine compound of structural Formula XX with peracetic acid or hydrogen peroxide.
  • a process for the preparation of an -methylpyrimidine derivative of structural Formula XXII comprising reaction of the sulphonyl derivative of structural Formula XXI with methylamine.
  • the methylamination can be carried out in a solvent, for example toluene, methylene chloride, tetrahydrofuran, dioxane, and a mixture thereof.
  • a process for the preparation of a pyrimidine aldehyde of structural Formula I comprising oxidation of alcoholic compound of structural Formula XVI with ⁇ -manganese dioxide.
  • the pyrimidine aldehyde of Fonnula I prepared by the process of the present invention can be subjected to ittig condensation with methyl (3R)-3- (tert- butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidene hexanate (phosphorane) of structural Formula III to provide a condensed product of structural Formula IV.
  • the condensed product is deprotected with methatiesulphonic acid to provide a keto alcohol of structural Formula V, which is further reduced to afford a dihydroxyheptenate of Formula VI, which is hydrolyzed to give rosuvastatin of structural Formula II as shown in Scheme ⁇ .
  • methyl (3R)-3- (tert-butyldimethylsilyloxy)-5-oxo-6- triphenylphosphoranylidene hexanate of structural Formula III may be prepared by methods known in the literature, for example as described in U.S. Patent No. 5,620,440.
  • Methods known in the art may be used with the process of this invention to enhance any aspect of the process. Any one familiar with organic process research development can do variations in various reaction parameters described above.
  • the product obtained may be further purified by any technique known to a person skilled in the art, for example, by filtration, crystallization, column chromatography, preparative high pressure liquid chromatography, preparative thin layer chromatography, extractive washing in solution or a combination of these procedures.
  • the dihydropyrimidine intermediate obtained above (108.0 g, 0.271 mole) and ⁇ - Mn ⁇ 2 (324 g) were taken in dichloromethane and the reaction mixture was stirred at 35°C for 30 to 60 minutes. The reaction mixture was filtered through celite and the solvent removed to yield a solid product.
  • benzylsulphonyl intermediate (40.0 g, 0.0934 mole) was taken in dichloromethane (500 ml) and cooled to -10°C to -15°C.
  • a solution of methylamine (7.98 g, 0.249 mole) in dichloromethane was added drop wise under cooling. The mixture was stirred at ambient temperature for few hours. The solution was filtered and the filtrate was washed with water, organic layer was dried over anhydrous sodium sulphate and the product was isolated in hexane at 0°C - 5°C.
  • Step h Preparation of 4-(4-FIuorophenhl)-6-isopropyl-2-(N-methyl-N- methylsuIphonylamino)-S-pyrimidinecarboxaldehyde (1) (Pyrimidine Aldehyde Intermediate)
  • Step a Preparation of Methyl 7-[4-(4-fluorophenyl)-6-isopropyl-2-(n-methyl-n- methyl sulphonylamino)-pyrimidin-5-yl]-(3r)-3-(tert-butyldimethyI silyloxy)-5-oxo- (e)-6 heptenate (IV) (Protected Heptenate)
  • Step c Preparation of (+)-(3r, 5s), methyl 7-[4-(4-fh ⁇ orophenyl)-6-isopropyl-2-(n- methyI-n-methyIsulphonylamino)-pyrimidin-5-yl]-3, 5-dihydroxy-6(e)-heptenate (VT) (Dihydroxy Heptenate)
  • Step e Preparation of (+)-(3r, 5s)-7-[4 ⁇ (4 ⁇ fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulphonyIamino)-pyrimidin-5-yl]-3, 5-dihydroxy-6(e)-heptenoic acid calcium salt (II) (Rosuvastatin Calcium Salt)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a cost effective and industrially advantageous process for the preparation of 4-4(fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulphonylamino)-5-pyrimidinecarboxaldehyde, referred to here as pyrimidine aldehyde of structural Formula I and to the use of this compound as intermediate for the preparation of rosuvastatin.

Description

PROCESS FOR THE PREPARATION OF ROSUVASTATIN
Field of the Invention
The present invention relates to a cost effective and industrially advantageous process for the preparation of 4-4(fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulρhonylammo)-5-pyrimidinecarboxaldehyde, referred to here as pyrimidine aldehyde of structural Formula I
Figure imgf000002_0001
FORMULA I and to the use of this compound as intermediate for the preparation of rosuvastatin or a pharmaceutically acceptable salt thereof.
Background of the Invention
Chemically, rosuvastatin is (+)-(3R, 5S)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N- methyl-N-methylsulphonylamino) pyrimidin-5-yl]-3, 5-dihydroxy-6(E)-heptenoic acid calcium salt (2:1) having the structural Formula II
Figure imgf000002_0002
FORMULA II Rosuvastatin is an antihypercholesterolemic drug used in the treatment of atherosclerosis.
Hypercholesterolemia is now well recognized as a primary risk in coronary heart disease. Clinical studies with lipid lowering agents have established that decreasing elevated serum cholesterol level reduces the incidence of cardiovascular mortality. Recently, it has been found that rosuvastatin calcium has consistently shown greater potency than other currently marketed statins (atorvastatin, simvastatin and pravastatm) in preclinical and clinical testing.
Rosuvastatin and a process for its preparation are disclosed in U.S. Patent No. 5,260,440. The process disclosed therein involves four distinct chemical steps: (1) condensation of methyl (3R)-3-(rert-butyldimethylsilyloxy)-5-oxo-6- triphenylphosphoranylidene hexanate, referred to here as phosphorane with 4-(4- fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)-5- pyrimidinecarboxaldehyde, referred to here as pyrimidine aldehyde; (2) deprotection of the 3-hydroxyl group to give a keto alcohol; (3) reduction of 5-oxo to get a chiral dihydroxy heptenate; and (4) hydrolysis of the dihydroxy heptenate and conversion to hemicalcium salt.
The generation of the pyrimidine aldehyde requires eight synthetic steps and involves the use of expensive reagents and toxic solvents. The process results in the formation of several side products at various intermediate steps thus necessitating purification at the cost of low yields. The process is both uneconomical and time consuming, hence not suitable for commercial production.
It is, therefore, desirable to provide an efficient process for the preparation of rosuvastatin which improves the economics by employing less expensive reagents and is more productive.
Summary of the Invention
The present invention provides a process for the preparation of rosuvastatin, its salts, esters, or the corresponding cyclized lactone form. The process provides obvious benefits with respect to economics and convenience to operate on a commercial scale. Detailed Description of the Invention
In accordance with one aspect, there is provided a process for the preparation of 4- (4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulphonylamino)-5- pyrimidinecarboxaldehyde of structural Formula I as shown in Scheme I,
Figure imgf000004_0001
FORMULA I
SCHEME I
Figure imgf000005_0001
xvπ xviπ Stepb
Figure imgf000005_0002
XVT comprising: a. condensing 4-fluorobenzaldehyde of structural Formula VIII with a compound of structural Formula XVII, wherein Ri is independently C2-6 alkyl, Cι-6 cycloalkyl or aralkyl, to give an olefin of structural Formula xvπi, b. reacting the olefin with isothiourea of structural Formula IX, wherein R2 is independently C2-e alkyl, .6 cycloalkyl or aralkyl, to give a cyclized dihydropyrimidine derivative of structural Formula XIX, c. aromatization of the dihydropyrimidine derivative with γ-manganese dioxide to give a pyrimidine compound of structural Formula XX, d. oxidation of the pyrimidine compound to give a sulphonyl derivative of structural Foπnula XXI, e. subjecting the sulphonyl derivative to methylamination to give an N- methylpyrimidine derivative of structural Formula XXII, f. methanesulphonylation of the N-methylpyrimidine derivative to give an N- methyl methanesulphonamide derivative of structural Formula XXIII, g. reduction of the N-methyl methanesulphonamide derivative with diisobutylaluminium hydride (DIBAL) in toluene to give an alcoholic compound of structural Formula XVI, and h. oxidation of the alcoholic compound to give a pyrimidine aldehyde of structural Formula I.
The condensation at step a) can be carried out in a suitable solvent, for example . hexane, heptane, cycloheptane, cyclohexane, and mixture(s) thereof at a reflux temperature in the presence of piperidine and glacial acetic acid.
The cychzation at step b) can be carried out in a suitable solvent, for example N, N-dimethylacetamide, N, N-dimethylformamide, dimethylsulphoxide, acetonitrile, and mixture(s) thereof in the presence of molecular sieves.
The aromatization at step c) can be carried out with γ-manganese dioxide in the presence of a solvent, for example dichloromethane, chloroform, toluene, benzene, ethyl acetate, and mixture(s) thereof. The oxidation reaction at step d) can be carried out with peracetic acid or hydrogen peroxide in a solvent, for example dichloromethane, chloroform, toluene, benzene, ethyl acetate, and mixture(s) thereof.
The methylamination at step e) can be carried out with methylamine in a solvent, for example toluene, methylene chloride, tetrahydrofuran, dioxane, and mixture(s) thereof.
The methanesulphonation at step f) can be carried out in the presence of n- butyllithium.
The selective oxidation of the alcoholic compound at step h) can be carried out with γ-manganese dioxide in a suitable solvent, for example methylene chloride, tetrahydrofuran, dioxane, and mixture(s) thereof to give a pyrimidine aldehyde of structural Formula I.
The reactions (a) to (h) of Scheme I can be performed and worked up in a manner conventional for the type of reaction involved. The reaction parameters such as concentration, reaction duration, temperature, molar ratios of reagents can be chosen according to principles well established in the art.
In accordance with a second aspect, there is provided a process for the preparation of cyclized dihydropyrimidine derivative of structural Formula XIX comprising reaction of an olefin of structural Formula XVIII with isothiourea of structural Formula IX, wherein R2 is independently C2-6 alkyl, Ci-β cycloalkyl or aralkyl.
In accordance with a third aspect, there is provided a process for the preparation of a pyrimidine compound of structural Formula XX comprising aromatization of the dihydropyrimidine derivative of structural Formula XIX with γ-manganese dioxide.
In accordance with a fourth aspect, there is provided a process for the preparation of a sulphonyl derivative of structural Formula XXI comprising oxidation of the pyrimidine compound of structural Formula XX with peracetic acid or hydrogen peroxide. tα accordance with a fifth aspect, there is provided a process for the preparation of an -methylpyrimidine derivative of structural Formula XXII comprising reaction of the sulphonyl derivative of structural Formula XXI with methylamine. The methylamination can be carried out in a solvent, for example toluene, methylene chloride, tetrahydrofuran, dioxane, and a mixture thereof.
In accordance with a sixth aspect, there is provided a process for the preparation of a pyrimidine aldehyde of structural Formula I comprising oxidation of alcoholic compound of structural Formula XVI with γ-manganese dioxide.
In another aspect, the pyrimidine aldehyde of Fonnula I prepared by the process of the present invention can be subjected to ittig condensation with methyl (3R)-3- (tert- butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidene hexanate (phosphorane) of structural Formula III to provide a condensed product of structural Formula IV. The condensed product is deprotected with methatiesulphonic acid to provide a keto alcohol of structural Formula V, which is further reduced to afford a dihydroxyheptenate of Formula VI, which is hydrolyzed to give rosuvastatin of structural Formula II as shown in Scheme π.
SCHEME II
Figure imgf000009_0001
Figure imgf000009_0002
The starting material, methyl (3R)-3- (tert-butyldimethylsilyloxy)-5-oxo-6- triphenylphosphoranylidene hexanate of structural Formula III may be prepared by methods known in the literature, for example as described in U.S. Patent No. 5,620,440.
Methods known in the art may be used with the process of this invention to enhance any aspect of the process. Any one familiar with organic process research development can do variations in various reaction parameters described above. The product obtained may be further purified by any technique known to a person skilled in the art, for example, by filtration, crystallization, column chromatography, preparative high pressure liquid chromatography, preparative thin layer chromatography, extractive washing in solution or a combination of these procedures.
The examples mentioned below demonstrate specific preparations of the present invention. The examples are provided to illustrate the details of the invention and should not be constrained to limit the scope of the present invention.
EXAMPLE 1
Preparation Of 4-(4-FIuorophenyl)-6-isopropyl-2-(N-methylsulphonylamino)-5- pyrimidinecarboxaldehyde (I) (Pyrimidine Aldehyde)
Step a - Preparation of Methyl 3-(4-fluorophenyl)-2-(2-methyl-l-oxopropyl)-prop-2- enoate (XVIII) (Olefin)
To amixture of piperidine (1.06gm, 0.18 mmoles equivalent) and glacial acetic acid (2.08gm, 0.5 moles equivalent) in hexane (110ml), was added 4-fluorobenzaldehyde (8.7gm, 1.01 moles equivalent) and methylisobutyryl acetate (lOgm, 1 mole equivalent) at room temperature. The reaction mixture was heated to reflux with simultaneous removal of water azeotropically for 12-16 hours. After the reaction was over, the mixture was cooled and dimethylformamide (10ml) was added. It was stirred and the organic portion was washed with 10% aqueous sodium metabisulphite, 5% dilute hydrochloric acid and 10% brine. The evaporation of the solvent gave olefin as a semi-solid. Yield: 100% (GC Purity >98%). Step b - Preparation of Methyl 4-(4-fluoro-phenyl)-6-isopropyl-2-benzylthio-3h- pyrimidine-5-carboxylate (XIX) (Dihydropyrimidine Intermediate)
A mixture of the compound of Formula XVIII (75 g, 0.3 mole), S-benzylisothioureahydrochloride (60.81 g, 0.3 mole) and molecular sieves (300 g) in N, N-dimethylformamide (375 ml) was stirred at room temperature for 6-10 hours and then slowly heated to 85°C-90°C for 6-10 hours. After the reaction was over, the mixture was cooled to room temperature and filtered through celite. The mixture was then washed with 5% sodium bicarbonate followed by 5% dilute hydrochloric acid and 10% brine. The organic portion was then concentrated and crystallized in isopropyl ether yielding the dihydropyrimidine intermediate (XIX) as a pure white solid. Yield: 0.81 % (HPLC quality >98%)
Step c - Preparation of Methyl 4~(4-fluorophenyl)-6-isopropyl-2-benzylthio- pyrimidine-5-carboxylate (XX) (Pyrimidine Compound)
The dihydropyrimidine intermediate obtained above (108.0 g, 0.271 mole) andγ- Mnθ2 (324 g) were taken in dichloromethane and the reaction mixture was stirred at 35°C for 30 to 60 minutes. The reaction mixture was filtered through celite and the solvent removed to yield a solid product.
Yield: 100% (HPLC quality > 97%)
Step d - Preparation of Methyl 4-(4-fluorophenyl)-6-isopropyl)-6-isopropyl-2- benzylsulphonyl pyrimidine-5-carboxyIate (XXI) (Benzenesulphonyl Intermediate)
To a solution of the pyrimidine compound, XX (45.0 g, 0.113 mole) in dichloromethane at 25°C - 28°C, was added peracetic acid (112.5 ml) drop wise. The reaction mixture was stirred for few hours at 33°C - 34°C. After the reaction was over, 5% aqueous solution of sodium hydrogen carbonate was added drop wise. The organic layer was separated and dried over anhydrous sodium sulphate. The title compound was isolated in methanol as a solid.
Yield: 95% (HPLC quality>99%). Step e - Preparation of Methyl 4-(4-fluorophenyl)-6-isopropyI-2-(n-methylamino) pyrimidine-5-carboxyIate (XXII) (N-methyl Pyrimidine Intermediate)
The above obtained benzylsulphonyl intermediate (40.0 g, 0.0934 mole) was taken in dichloromethane (500 ml) and cooled to -10°C to -15°C. A solution of methylamine (7.98 g, 0.249 mole) in dichloromethane was added drop wise under cooling. The mixture was stirred at ambient temperature for few hours. The solution was filtered and the filtrate was washed with water, organic layer was dried over anhydrous sodium sulphate and the product was isolated in hexane at 0°C - 5°C.
Yield: 100% (HPLC quality >99%)
Step f - Preparation of Methyl 4-(4-fluorophenyl)-6-isopropyl-2-(n-methyl-n- methylsulphonylamino) pyrimidine-5-carboxylate (XXIII) (Sulphonamide Intermediate)
The intermediate N-methylpyrimidine (36.0 g, 0.11 mole) obtained above was taken in tetrahydroftiran (360 ml) and cooled to -70°C to -75°C. A solution of N- butyllithium in hexane (1.6 molar, 150.0 ml) was added drop wise under cooling. The reaction mixture was stirred for a few hours followed by drop wise addition of methanesulphonyl chloride (30.6 g, 0.26 mole). After the reaction was over, water (340ml) was added slowly and the tetrahydrofuran layer was concentrated to get an oily residue. This was taken in ethyl acetate (540ml) and washed with 5% sodium bicarbonate and 10% brine. The solvent was evaporated to give crude N-methyl methanesulphonamide intermediate as a solid material. The isolation from diisopropyl ether gave the title compound as a pure solid product. Yield: 63% (HPLC Quality >98%)
Step g - Preparation of [4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulphonylamino) pyrimidin-5-yl] methanol (XVI) (Pyrimidine Alcohol Intermediate)
To a solution of the above obtained compound (7.0 g, 0.0183 mole) in toluene (70 ml), was added drop wise DIBAL (20% solution in toluene; 47.6 ml) at -70°C to -75°C and stirred the solution for few hours. After the reaction was over, it was quenched with saturated ammonium chloride solution followed by filtration of the reaction mixture through celite. The filtrate was treated with charcoal and the solvent was removed to yield pyrimidine alcohol (XVI).
Yield: 80% (HPLC Quality >99%).
Step h - Preparation of 4-(4-FIuorophenhl)-6-isopropyl-2-(N-methyl-N- methylsuIphonylamino)-S-pyrimidinecarboxaldehyde (1) (Pyrimidine Aldehyde Intermediate)
To the above obtained pyrimidine alcohol (lg), was added dichloromethane (10 ml) followed by the addition of γ-active manganese dioxide (6 g). The reaction mixture was stirred at room temperature for few hours followed by refluxing for 8-10 hours. After the reaction was over, it was filtered through celite. The removal of solvent followed by crystallization in toluene- ethyl acetate mixture gave pyrimidine aldehyde (I). Yield: 80.5% (HPLC Quality >99%).
EXAMPLE 2
Preparation of Rosuvastatin
Step a - Preparation of Methyl 7-[4-(4-fluorophenyl)-6-isopropyl-2-(n-methyl-n- methyl sulphonylamino)-pyrimidin-5-yl]-(3r)-3-(tert-butyldimethyI silyloxy)-5-oxo- (e)-6 heptenate (IV) (Protected Heptenate)
A solution of lOOg of pyrimidine aldehyde, 228g of phosphorane,methyl (3R)-3- (tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanate and 1500 ml of toluene was refluxed for about 30 hours and the reaction mixture was concentrated under reduced pressure. Cyclohexane (1500 ml) was added and the solution was cooled to 10°C and stirred for 2 hours at 10°C - 12°C. The solution was filtered and concentrated under vacuum. The concentrate so obtained was dissolved in cyclohexane (1000 ml) and the residue was discarded. The solution so obtained was concentrated to 500 ml, cooled and filtered. The filtrate was concentrated under vacuum to give thick oil.
Yield: 100% Step b - Preparation of Methyl 7-[4-(4-fluorophenyl)-6-isopropyl-2-(n-methyl-n- methyl sulphonylamino)-pyrimidin-S-yl]-(3r)-3-hydroxy-5-oxo-[e)-6-heptenate (V) (Keto Alcohol Intermediate)
To the compound of Formula IV (100g) in methanol (1000 ml), was added a solution of methanesulphonic acid ( 10 g) in water ( 190 ml) at 15°C . The reaction mixture was stirred for 6 hours at 30CC - 35°C and concentrated under vacuum. The residue was extracted with dichloromethane (750 ml), washed with water (300 ml) and with aqueous sodium bicarbonate (1% w/v; 300 ml). The solution was concentrated under vacuum to give thick oil.
Yield: 96%
Step c - Preparation of (+)-(3r, 5s), methyl 7-[4-(4-fhιorophenyl)-6-isopropyl-2-(n- methyI-n-methyIsulphonylamino)-pyrimidin-5-yl]-3, 5-dihydroxy-6(e)-heptenate (VT) (Dihydroxy Heptenate)
To a solution of 13g of the compound of Formula V in 350 ml of anhydrous tetrahydrofuran and 90ml of methanol, was added a solution of 13 ml of 1M diethylmethoxyborane in tetrahydrufuran at -78°C, and the mixture was stirred at the same temperature for 30 minutes. To the mixture, was added 1.3g of a sodium borohydride and the mixture was stirred for another 3 hours. Acetic acid (16ml) was added thereto, and the mixture was adjusted to pH 8 with saturated sodium bicarbonate and extracted with ether. The organic layer was washed with water, dried and evaporated ether under reduced pressure. To the resulting residue, methanol was added and the mixture was evaporated under reduced pressure. The resulting residue was subjected to column chromatography of silica gel eluting with methylene chloride / ether (3:1) to give 11.4g of dihydroxy compound, methyl 7-[4-fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulphonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenate (VI) as syrup. Yield: 85.2% Step d - Preparation of (+)-(3r, 5s)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulphonylamino)-pyrimidin-5-yl]-3, 5-dihydroxy-6(e)-heptenoic acid sodium salt (VII) (Rosuvastatin Sodium Salt)
To a solution of 11.4g of the compound of Formula VI in 160ml of ethanol, was added 100ml of 0.25 N sodium hydroxide under ice-cooling. The reaction mixture was warmed to room temperature and stirred for 1 hour. The solution was concentrated to remove the organic solvent under vacuum at 35°C - 40°C. The aqueous layer was washed with methyl tertiary butyl ether (MTBE) (500x2ml) twice and filtered through a hyflo bed. The aqueous layer was used as such in the next step.
Step e - Preparation of (+)-(3r, 5s)-7-[4~(4~fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulphonyIamino)-pyrimidin-5-yl]-3, 5-dihydroxy-6(e)-heptenoic acid calcium salt (II) (Rosuvastatin Calcium Salt)
To the aqueous solution of rosuvastatin sodium obtained from the previous step, was added an aqueous solution of calcium acetate and the reaction mixture was stirred for 2 hours at room temperature. The reaction mixture was filtered, washed with water (100 ml) and dried at 40°C-45° C under vacuum for 6 hours to get 9.0 g of rosuvastatin calcium.
Yield: 80.7%
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

Claims

WE CLAIM:
1. A process for the preparation of 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulphonylamino) pyrimidin-5-yl]carboxaldehyde of structural Formula I,
Figure imgf000016_0001
FORMULA I comprising: a. condensing 4-fluorobenzaldehyde of structural Formula VIII
Figure imgf000016_0002
FORMULA VIII with a compound of structural Formula XVII, wherein Ri is independently C2-6 alkyl, C1-6 cycloalkyl or aralkyl,
Figure imgf000016_0003
FORMULA XVII o give an olefin of structural Formula XVIII,
Figure imgf000017_0001
FORMULA XVIII b. reacting the olefin with isothiourea of structural Formula IX, wherein R is independently C2-6 alkyl, Ci-β cycloalkyl or aralkyl,
Figure imgf000017_0002
FORMULA IX to give a cyclized dihydropyrimidine derivative of structural Formula XIX,
Figure imgf000017_0003
FORMULA XIX c. aromatizing the dihydropyrimidine derivative with γ-manganese dioxide to give a pyrimidine compound of structural Formula XX,
Figure imgf000018_0001
FORMULA XX d. oxidizing the pyrimidine compound to give a sulphonyl derivative of structural Formula XXI,
Figure imgf000018_0002
FORMULA XXI e. reacting the sulphonyl derivative with methylamine to give an N- methylpyrimidine derivative of structural Formula XXII,
Figure imgf000018_0003
FORMULA XXII f. reacting the N-methyl pyrimidine derivative with methanesulphonyl chloride to give an N-methyl methanesulphonamide derivative of structural Formula XXIII,
Figure imgf000019_0001
FORMULA XXIII g. reducing the N-methyl methanesulphonamide derivative with diisobutylaluminium hydride (DIBAL) in toluene to give an alcoholic compound of structural Formula XVI, and
Figure imgf000019_0002
FORMULA XVI h. oxidizing the alcoholic compound to give a pyrimidine aldehyde of structural Formula I.
2. The process according to claim 1, wherein step (a) is carried out in a suitable solvent at reflux temperature in the presence of piperidine and glacial acetic acid.
3. The process according to claim 2, wherein the solvent is selected from the group consisting of hexane, heptane, cyclopentane, cyclohexane, and mixture(s) thereof.
4. The process according to claim 3, wherein the solvent is hexane.
5. The process according to claim 1, wherein step (b) is carried out in the presence of molecular sieves.
6. The process according to claim 1 , wherein step (b) is carried out in a suitable solvent.
7. The process according to claim 6, wherein the solvent is selected from the group consisting of N,N-dimethylacetamide, N,N-dimethylformamide, dimethylsulphoxide, acetonitrile, and mixture(s) thereof.
8. The process according to claim 1, wherein step (c) is carried out in a solvent.
9. The process according to claim 8, wherein the solvent is selected from the group consisting of dichloromethane, chloroform, toluene, benzene, ethyl acetate, and mixture(s) thereof.
10. The process according to claim 1, wherein step (d) is performed with peracetic acid or hydrogen peroxide.
11. The process according to claim 11 , wherein step (d) is performed with peracetic acid.
12. The process according to claim 1, wherein step (d) is carried out in a solvent.
13. The process according to claim 12, wherem the solvent is selected from the group consisting of dichloromethane, chloroform, toluene, benzene, ethyl acetate, and mixture(s) thereof.
14. The process according to claim 1, wherein step (e) is carried out in a solvent.
15. The process according to claim 14, wherein the solvent is selected from the group consisting of toluene, methylene chloride, tetrahydrofuran, dioxane, and mixture(s) thereof.
16. The process accordmg to claim 1, wherein step (f) is performed in the presence of n- butyl lithium.
17. The process according to claim 1, wherein step (h) is carried out in the presence of γ- manganese dioxide.
18. The process according to claim 1, wherein step (h) is carried out in a solvent.
19. The process according to claim 17, wherein the solvent is selected from the group consisting of methylene chloride, tetrahydrofuran, dioxane, and mixture(s) thereof.
0. A process for the preparation of cyclized dihydropyrimidine derivative of structural Formula XIX, wherein Ri and R2 are independently C2.6 alkyl, Cι-6 cycloalkyl or aralkyl,
Figure imgf000021_0001
FORMULA XIX comprising reacting an olefin of structural Formula XVIII, wherein Ri is as defined earlier,
Figure imgf000021_0002
FORMULA XVIII with isothiourea of structural Formula IX, wherein R2 is as defined earlier.
Figure imgf000021_0003
FORMULA IX
21. The process of claim 20, wherein the isothiourea is S-benzylisothiourea.
22. A process for the preparation of a pyrimidine compound of structural Formula XX, wherein Ri and R2 are independently C2-6 alkyl, Cι.6 cycloalkyl or aralkyl,
Figure imgf000022_0001
FORMULA XX comprising aromatizing a dihydropyrimidine derivative of structural Formula XIX, wherein Ri and R2 are as defined earlier, with γ-manganese dioxide.
Figure imgf000022_0002
FORMULA XIX
23. A process for the preparation of a sulphonyl derivative of structural Formula XXI, wherein Ri and R2 are independently C2-6 alkyl, Cι-6 cycloalkyl or aralkyl,
Figure imgf000022_0003
FORMULA XXI comprising oxidizing a pyrimidine compound of structural Formula XX, wherein i and R2 are as defined earlier, with peracetic acid or hydrogen peroxide.
Figure imgf000023_0001
FORMULA XX
24. The process of claim 23, wherein the pyrimidine compound of structural Formula XX is oxidized with peracetic acid.
25. A process for the preparation of an N-methylpyrimidine derivative of structural Formula XXII, wherein Ri and R2 are independently C2.6 alkyl, Ci-s cycloalkyl or aralkyl,
Figure imgf000023_0002
FORMULA XXπ comprising reacting a sulphonyl derivative of structural Formula XXI, wherein Ri is as defined earlier and R2 is independently C2-6 alkyl, Ci-β cycloalkyl or aralkyl, with methylamine.
Figure imgf000023_0003
FORMULA XXI
26. The process according to claim 25, wherein the reaction is carried out in a solvent.
27. The process according to claim 26, wherein the solvent is selected from the group consisting of toluene, methylene chloride, tetrahydrofuran, dioxane, and mixture(s) thereof.
28. A process for the preparation of 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulphonylamino) pyrimidin-5-yl]carboxaldehyde of structural Formula I,
Figure imgf000024_0001
FORMULA I
comprising oxidizing alcoholic compound of structural Formula XVI,
Figure imgf000024_0002
FORMULA XVI with γ-manganese dioxide to give the compound of structural Formula I.
9. A process for the preparation of rosuvastatin or a pharmaceutically acceptable salt thereof of structural Formula II,
Figure imgf000025_0001
FORMULA II compnsing: a. condensing 4-fluorobenzaldehyde of structural Formula VIII
Figure imgf000025_0002
FORMULA VIII with a compoxmd of structural Formula XVII, wherein Ri is independently C2-6 alkyl, Ci-β cycloalkyl or aralkyl,
Figure imgf000025_0003
FORMULA XVII to give an olefin of structural Formula XVIII,
Figure imgf000026_0001
FORMULA XVIII b. reacting the olefin with isothiourea of structural Formula IX, wherein R2 is independently C2-6 alkyl, Cι-6 cycloalkyl or aralkyl,
Figure imgf000026_0002
FORMULA IX to give a cyclized dihydropyrimidine derivative of structural Formula XIX,
Figure imgf000026_0003
FORMULA XIX c. aromatizing the dihydropyrimidine derivative with γ-manganese dioxide to give a pyrimidine compound of structural Formula XX,
Figure imgf000027_0001
FORMULA XX d. oxidizing the pyrimidine compound to give a sulphonyl derivative of structural Formula XXI,
Figure imgf000027_0002
FORMULA XXI e. reacting the sulphonyl derivative with methylamine to give an N- methylpyri idine derivative of structural Formula XXII,
Figure imgf000027_0003
FORMULA XXII f. reacting the N-methyl pyrimidine derivative with methanesulphonyl chloride to give an N-methyl methanesulphonamide derivative of structural Formula XXIII,
Figure imgf000028_0001
FORMULA XXIII g. reducing the N-methyl methanesulphonamide derivative with diisobutylaluminium hydride (DIBAL) in toluene to give an alcoholic compound of structural Formula XVI,
Figure imgf000028_0002
FORMULA XVI
h, oxidizing the alcohohc compound to give a pyrimidine aldehyde of structural Formula I,
Figure imgf000029_0001
FORMULA I
i. condensing the compound of structural Formula I with methyl (3R)-3- (tert- butyldimethylsilyloxy)-5-oxo-6-triphenyl-phosphoranylidene hexanate of structural Formula III,
O OTBDMS
Ph3^ J X. /COOCH3
(OTBDMS=OSi(CH3)2t-Bu) FORMULA III to give a condensed product of structural Formula IV,
Figure imgf000029_0002
FORMULA IV j. deprotecting the condensed product with methanesulphomc acid to give a keto alcohol of structural Formula V,
Figure imgf000030_0001
FORMULA V reducing the keto alcohol to give a dihydroxyheptenate of structural Formula VI, and
Figure imgf000030_0002
FORMULA VI
1. hydrolyzing the dihydroxyheptenate to give rosuvastatin of structural Formula II.
30. The process according to claim 29, wherein step (h) is carried out in the presence of γ-manganese dioxide.
PCT/IB2003/001946 2002-05-21 2003-05-21 Process for the preparation of rosuvastatin WO2003097614A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003228010A AU2003228010A1 (en) 2002-05-21 2003-05-21 Process for the preparation of rosuvastatin
US10/515,361 US20050222415A1 (en) 2002-05-21 2003-05-21 Process for the preparation of rosuvastatin
BR0311195-4A BR0311195A (en) 2002-05-21 2003-05-21 Rosuvastatin Preparation Process
EA200401533A EA200401533A1 (en) 2002-05-21 2003-05-21 METHOD OF OBTAINING ROSUVASTATIN
EP03725478A EP1585736A2 (en) 2002-05-21 2003-05-21 Process for the preparation of rosuvastatin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN575DE2002 2002-05-21
IN575/DEL/2002 2002-05-21

Publications (2)

Publication Number Publication Date
WO2003097614A2 true WO2003097614A2 (en) 2003-11-27
WO2003097614A3 WO2003097614A3 (en) 2004-05-21

Family

ID=29434392

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/001946 WO2003097614A2 (en) 2002-05-21 2003-05-21 Process for the preparation of rosuvastatin

Country Status (7)

Country Link
US (1) US20050222415A1 (en)
EP (1) EP1585736A2 (en)
AR (1) AR039836A1 (en)
AU (1) AU2003228010A1 (en)
BR (1) BR0311195A (en)
EA (1) EA200401533A1 (en)
WO (1) WO2003097614A2 (en)

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021511A1 (en) * 2003-08-27 2005-03-10 Hetero Drugs Limited A novel process for amorphous rosuvastatin calcium
WO2005023778A3 (en) * 2003-08-28 2005-06-16 Teva Pharma Process for preparation of rosuvastatin calcium
WO2006017357A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
WO2006076845A1 (en) * 2005-01-19 2006-07-27 Anhui Qingyun Pharmaceutical And Chemical Co., Ltd Process for producing rosuvastatin calcium, intermediate for the preparation of the same and process for producing the intermediate
WO2006091771A2 (en) 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
WO2006100689A1 (en) * 2005-03-22 2006-09-28 Unichem Laboratories Limited Process for preparation of rosuvastatin
WO2006106526A1 (en) * 2005-04-04 2006-10-12 Unichem Laboratories Limited Process for preparation of calcium salt of rosuvastatin
WO2006128954A1 (en) * 2005-06-01 2006-12-07 Fermion Oy Process for the preparation of n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide
WO2006136407A1 (en) * 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Process for preparing amorphous rosuvastatin calcium free of impurities
WO2007040940A1 (en) * 2005-10-03 2007-04-12 Teva Pharmaceutical Industries Ltd. Diastereomeric purification of rosuvastatin
WO2007022488A3 (en) * 2005-08-16 2007-05-03 Teva Pharma Crystalline rosuvastatin intermediate
WO2007074391A2 (en) * 2005-12-28 2007-07-05 Bakulesh Mafatlal Khamar Preparation of a key intermediate in the synthesis of rosuvastatin
US7244844B2 (en) 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
EP1816126A1 (en) * 2003-08-28 2007-08-08 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
CZ298330B6 (en) * 2004-07-19 2007-08-29 Zentiva, A. S. Process for preparing 4-(4--fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyl-amino)-5-pyrimidinecarbaldehyde and use thereof
US7304156B2 (en) 2001-07-13 2007-12-04 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
WO2008036286A1 (en) * 2006-09-18 2008-03-27 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
WO2008072078A1 (en) * 2006-12-13 2008-06-19 Aurobindo Pharma Limited An improved process for preparing rosuvastatin caclium
WO2008093205A2 (en) * 2007-01-31 2008-08-07 Orchid Chemicals & Pharmaceuticals Limited A method for the purification of rosuvastatin intermediate
CN100436428C (en) * 2005-08-22 2008-11-26 鲁南制药集团股份有限公司 Preparation method of rosuvastain and its salt
WO2008151510A1 (en) * 2007-06-11 2008-12-18 Anhui Qingyun Pharmaceutical And Chemical Co., Ltd. Preparation of 4-(fluorophenyl)-6-isopropyl-2-(n-methyl-n-methylsulfonylamino)- 5-formyl-pyrimidine
EP2022784A1 (en) * 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
US7511140B2 (en) 2002-08-13 2009-03-31 Astrazeneca Ab Process for preparing the calcium salt of rosuvastatin
EP2062903A1 (en) 2007-04-18 2009-05-27 Teva Pharmaceutical Industries Ltd. Statin intermediates and process for the preparation of statins
WO2009143776A1 (en) 2008-05-27 2009-12-03 常州制药厂有限公司 Preparation method of rosuvastatin calcium and its intermediates
WO2010081861A1 (en) 2009-01-14 2010-07-22 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of rosuvastatin
WO2010082072A1 (en) 2009-01-15 2010-07-22 Egis Gyógyszergyár Process for the preparation of rosuvastatin salts
US7777034B2 (en) 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
EP2223909A1 (en) 2007-08-28 2010-09-01 Ratiopharm GmbH Process for preparing pentanoic diacid derivatives
WO2010098583A2 (en) * 2009-02-24 2010-09-02 한미약품 주식회사 Novel method for preparing statin compounds or salts thereof, and intermediate compounds used in same
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US7884226B2 (en) 2007-07-12 2011-02-08 Teva Pharmaceutical Industries, Ltd. Purification of rosuvatatin intermediate by thin film evaporation and chemical method
CN1763015B (en) * 2004-10-22 2011-06-22 四川抗菌素工业研究所有限公司 Preparation method and intermediate of rosuvastatin and its pharmaceutical salts
KR101045895B1 (en) * 2005-02-22 2011-07-01 테바 파마슈티컬 인더스트리즈 리미티드 Preparation of rosuvastatin
WO2011141934A1 (en) 2010-05-13 2011-11-17 Matrix Laboratories Ltd. An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
US8063213B2 (en) 2003-06-05 2011-11-22 Astrazeneca Uk Limited Production of rosuvastatin calcium salt
WO2012011129A2 (en) * 2010-07-22 2012-01-26 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
WO2012073055A1 (en) 2010-11-29 2012-06-07 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Method for the preparation of high-purity pharmaceutical intermediates
US8212035B2 (en) 2007-02-08 2012-07-03 Aurobindo Pharma Ltd. Process for preparation of rosuvastatin calcium field of the invention
US8318933B2 (en) 2006-10-31 2012-11-27 Aurobindo Pharma Ltd Process for preparing rosuvastatin calcium
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
US8436167B2 (en) 2003-09-10 2013-05-07 Astrazeneca Uk Limited Chemical compounds
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
CN103134893A (en) * 2013-01-25 2013-06-05 峨眉山天梁星制药有限公司 High performance liquid chromatography of 3-tert-butyl dimethyl silica glutaric anhydride
US20130143908A1 (en) * 2010-08-04 2013-06-06 Porton Fine Chemicals Ltd. Method for preparing rosuvastatin calcium intermediate
WO2013080219A2 (en) 2011-11-28 2013-06-06 Mylan Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF INTERMEDIATES OF HMG-CoA REDUCTASE INHIBITORS
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
US9371291B2 (en) 2003-10-24 2016-06-21 Astrazeneca Uk Limited Process for the manufacture of the calcium salt of rosuvastatin (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-enoic acid and crystalline intermediates thereof
CN111548312A (en) * 2020-06-01 2020-08-18 雅本化学股份有限公司 Rosuvastatin calcium tablet and preparation process thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100622494B1 (en) * 2004-09-06 2006-09-19 현대자동차주식회사 steering wheel assembly structure
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
TW200800918A (en) * 2005-08-16 2008-01-01 Teva Pharma Rosuvastatin calcium with a low salt content
EP2350025A1 (en) * 2008-09-30 2011-08-03 Aurobindo Pharma Limited An improved process for preparing pyrimidine propenaldehyde
CN113754590B (en) * 2021-09-06 2023-06-13 浙江乐普药业股份有限公司 Preparation method of rosuvastatin calcium intermediate

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698326A (en) * 1954-12-28 S-aminomethylpyrimtoines
EP0521471A1 (en) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives as HMG-CoA reductase inhibitors
JPH07118233A (en) * 1993-10-19 1995-05-09 Shionogi & Co Ltd Production of pyrimidine derivative
EP1035127A1 (en) * 1999-03-10 2000-09-13 Lonza AG Process for the preparation of N-[5-(Diphenylphosphinoylmethyl)-4-(4-fluorphenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethansulfonamide
WO2001060804A1 (en) * 2000-02-15 2001-08-23 Astrazeneca Ab Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2003016317A1 (en) * 2001-08-16 2003-02-27 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4338866C1 (en) * 1993-11-13 1995-06-14 Wolf Gmbh Richard Medical instrument for the application of hot gas

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698326A (en) * 1954-12-28 S-aminomethylpyrimtoines
EP0521471A1 (en) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives as HMG-CoA reductase inhibitors
JPH07118233A (en) * 1993-10-19 1995-05-09 Shionogi & Co Ltd Production of pyrimidine derivative
EP1035127A1 (en) * 1999-03-10 2000-09-13 Lonza AG Process for the preparation of N-[5-(Diphenylphosphinoylmethyl)-4-(4-fluorphenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethansulfonamide
WO2001060804A1 (en) * 2000-02-15 2001-08-23 Astrazeneca Ab Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2003016317A1 (en) * 2001-08-16 2003-02-27 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRAUL, A. ET AL: "ZD-4522. Hypolipidemic HMG-CoA reductase inhibitor" DRUGS OF THE FUTURE (1999), 24(5), 511-513 , XP000882032 *
WATANABE, MASAMICHI ET AL: "Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a nove series of HMG-CoA reductase inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY (1997), 5(2), 437-444 , XP000911018 *

Cited By (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222412B2 (en) 2001-07-13 2012-07-17 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
US7816528B2 (en) 2001-07-13 2010-10-19 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
US8614320B2 (en) 2001-07-13 2013-12-24 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
US7304156B2 (en) 2001-07-13 2007-12-04 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
US7511140B2 (en) 2002-08-13 2009-03-31 Astrazeneca Ab Process for preparing the calcium salt of rosuvastatin
US7842807B2 (en) 2002-08-13 2010-11-30 Astrazeneca Uk Limited Process for preparing the calcium salt of rosuvastatin
US8063213B2 (en) 2003-06-05 2011-11-22 Astrazeneca Uk Limited Production of rosuvastatin calcium salt
WO2005021511A1 (en) * 2003-08-27 2005-03-10 Hetero Drugs Limited A novel process for amorphous rosuvastatin calcium
WO2005023778A3 (en) * 2003-08-28 2005-06-16 Teva Pharma Process for preparation of rosuvastatin calcium
US7396927B2 (en) 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
EP1816126A1 (en) * 2003-08-28 2007-08-08 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
US8436167B2 (en) 2003-09-10 2013-05-07 Astrazeneca Uk Limited Chemical compounds
US9371291B2 (en) 2003-10-24 2016-06-21 Astrazeneca Uk Limited Process for the manufacture of the calcium salt of rosuvastatin (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-enoic acid and crystalline intermediates thereof
US7777034B2 (en) 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
US8487097B2 (en) 2003-12-02 2013-07-16 Teva Pharmacedutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7692008B2 (en) 2003-12-02 2010-04-06 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7692010B2 (en) 2003-12-02 2010-04-06 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7741482B2 (en) 2003-12-02 2010-06-22 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7244844B2 (en) 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7692009B2 (en) 2003-12-02 2010-04-06 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US7655796B2 (en) 2004-07-13 2010-02-02 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvstatin
WO2006017357A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
CZ298330B6 (en) * 2004-07-19 2007-08-29 Zentiva, A. S. Process for preparing 4-(4--fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyl-amino)-5-pyrimidinecarbaldehyde and use thereof
CN1763015B (en) * 2004-10-22 2011-06-22 四川抗菌素工业研究所有限公司 Preparation method and intermediate of rosuvastatin and its pharmaceutical salts
WO2006076845A1 (en) * 2005-01-19 2006-07-27 Anhui Qingyun Pharmaceutical And Chemical Co., Ltd Process for producing rosuvastatin calcium, intermediate for the preparation of the same and process for producing the intermediate
US8049010B2 (en) * 2005-01-19 2011-11-01 Anhui Qingyun Pharmaceuticals & Chemical Co., Ltd. Synthetic method and intermediates of Rosuvastatin calcium and preparation methods of intermediates
WO2006091771A3 (en) * 2005-02-22 2007-01-11 Teva Pharma Ltd Preparation of rosuvastatin
KR100945763B1 (en) * 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 Preparation of rosuvastatin
KR101045895B1 (en) * 2005-02-22 2011-07-01 테바 파마슈티컬 인더스트리즈 리미티드 Preparation of rosuvastatin
US8063211B2 (en) 2005-02-22 2011-11-22 Teva Pharmaceutical Industries, Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
JP2007533764A (en) * 2005-02-22 2007-11-22 テバ ファーマシューティカル インダストリーズ リミティド Rosuvastatin free from rosuvastatin alkyl ether and salts thereof and method for producing them
US7582759B2 (en) 2005-02-22 2009-09-01 Teva Pharmaceutical Industries Ltd. Diastereomeric purification of rosuvastatin
US7612203B2 (en) 2005-02-22 2009-11-03 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
WO2006091771A2 (en) 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
WO2006091770A3 (en) * 2005-02-22 2007-05-31 Teva Pharma Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
WO2006100689A1 (en) * 2005-03-22 2006-09-28 Unichem Laboratories Limited Process for preparation of rosuvastatin
WO2006106526A1 (en) * 2005-04-04 2006-10-12 Unichem Laboratories Limited Process for preparation of calcium salt of rosuvastatin
WO2006128954A1 (en) * 2005-06-01 2006-12-07 Fermion Oy Process for the preparation of n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide
EP2508514A1 (en) 2005-06-24 2012-10-10 LEK Pharmaceuticals d.d. Process for preparing amorphous rosuvastatin calcium free of impurities
WO2006136407A1 (en) * 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Process for preparing amorphous rosuvastatin calcium free of impurities
AU2006261087B2 (en) * 2005-06-24 2010-09-30 Lek Pharmaceuticals D.D. Process for preparing amorphous rosuvastatin calcium free of impurities
US9150518B2 (en) 2005-06-24 2015-10-06 Lek Pharmaceuticals, D.D. Process for preparing amorphous rosuvastatin calcium of impurities
JP2008515931A (en) * 2005-08-16 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド Crystalline rosuvastatin intermediate
WO2007022488A3 (en) * 2005-08-16 2007-05-03 Teva Pharma Crystalline rosuvastatin intermediate
US7868169B2 (en) 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
CN100436428C (en) * 2005-08-22 2008-11-26 鲁南制药集团股份有限公司 Preparation method of rosuvastain and its salt
WO2007040940A1 (en) * 2005-10-03 2007-04-12 Teva Pharmaceutical Industries Ltd. Diastereomeric purification of rosuvastatin
JP2008526897A (en) * 2005-10-03 2008-07-24 テバ ファーマシューティカル インダストリーズ リミティド Diastereomeric purification of rosuvastatin
KR101019450B1 (en) * 2005-10-03 2011-03-07 테바 파마슈티컬 인더스트리즈 리미티드 Diastereomeric purification of rosuvastatin
WO2007074391A2 (en) * 2005-12-28 2007-07-05 Bakulesh Mafatlal Khamar Preparation of a key intermediate in the synthesis of rosuvastatin
WO2007074391A3 (en) * 2005-12-28 2008-06-26 Bakulesh Mafatlal Khamar Preparation of a key intermediate in the synthesis of rosuvastatin
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
JP2008539278A (en) * 2006-09-18 2008-11-13 テバ ファーマシューティカル インダストリーズ リミティド Crystalline rosuvastatin calcium
WO2008036286A1 (en) * 2006-09-18 2008-03-27 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
US7994178B2 (en) 2006-09-18 2011-08-09 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
US8318933B2 (en) 2006-10-31 2012-11-27 Aurobindo Pharma Ltd Process for preparing rosuvastatin calcium
US8212034B2 (en) 2006-12-13 2012-07-03 Aurobindo Pharma Ltd. Process for preparing rosuvastatin calcium
WO2008072078A1 (en) * 2006-12-13 2008-06-19 Aurobindo Pharma Limited An improved process for preparing rosuvastatin caclium
WO2008093205A3 (en) * 2007-01-31 2009-02-26 Orchid Chemicals & Pharm Ltd A method for the purification of rosuvastatin intermediate
WO2008093205A2 (en) * 2007-01-31 2008-08-07 Orchid Chemicals & Pharmaceuticals Limited A method for the purification of rosuvastatin intermediate
US8212035B2 (en) 2007-02-08 2012-07-03 Aurobindo Pharma Ltd. Process for preparation of rosuvastatin calcium field of the invention
EP2172471A2 (en) 2007-04-18 2010-04-07 Teva Pharmaceutical Industries Ltd. A process for preparing intermediates of HMG-CoA reductase inhibitors
US7687660B2 (en) 2007-04-18 2010-03-30 Teva Pharmaceutical Industries Ltd. Process for preparing intermediates of HMG-CoA reductase inhibitors
EP2062903A1 (en) 2007-04-18 2009-05-27 Teva Pharmaceutical Industries Ltd. Statin intermediates and process for the preparation of statins
US7964748B2 (en) 2007-04-18 2011-06-21 Teva Pharmaceutical Industries, Ltd. Process for preparing intermediates of HMG-CoA reductase inhibitors
EP2093230A1 (en) 2007-04-18 2009-08-26 Teva Pharmaceutical Industries Ltd. A process for preparing intermediates of HMG-CoA reductase inhibitors
WO2008151510A1 (en) * 2007-06-11 2008-12-18 Anhui Qingyun Pharmaceutical And Chemical Co., Ltd. Preparation of 4-(fluorophenyl)-6-isopropyl-2-(n-methyl-n-methylsulfonylamino)- 5-formyl-pyrimidine
US7884226B2 (en) 2007-07-12 2011-02-08 Teva Pharmaceutical Industries, Ltd. Purification of rosuvatatin intermediate by thin film evaporation and chemical method
EP2022784A1 (en) * 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
WO2009019211A1 (en) * 2007-08-08 2009-02-12 Lek Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
EP2848609A1 (en) 2007-08-08 2015-03-18 LEK Pharmaceuticals d.d. Crystalline methyl ester of rosuvastatin
US8309719B2 (en) 2007-08-08 2012-11-13 Lek Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
EP2223909A1 (en) 2007-08-28 2010-09-01 Ratiopharm GmbH Process for preparing pentanoic diacid derivatives
US8653265B2 (en) 2008-05-27 2014-02-18 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
WO2009143776A1 (en) 2008-05-27 2009-12-03 常州制药厂有限公司 Preparation method of rosuvastatin calcium and its intermediates
US8765947B2 (en) 2008-05-27 2014-07-01 Changzhou Pharmaceutical Factory Preparation method of Rosuvastatin calcium and its intermediates
WO2010081861A1 (en) 2009-01-14 2010-07-22 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of rosuvastatin
EP2752407A1 (en) 2009-01-14 2014-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Crystalline rosuvastatin calcium trihydrate
WO2010082072A1 (en) 2009-01-15 2010-07-22 Egis Gyógyszergyár Process for the preparation of rosuvastatin salts
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
WO2010098583A2 (en) * 2009-02-24 2010-09-02 한미약품 주식회사 Novel method for preparing statin compounds or salts thereof, and intermediate compounds used in same
WO2010098583A3 (en) * 2009-02-24 2011-01-06 한미홀딩스 주식회사 Novel method for preparing statin compounds or salts thereof, and intermediate compounds used in same
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
WO2011141934A1 (en) 2010-05-13 2011-11-17 Matrix Laboratories Ltd. An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
WO2012011129A2 (en) * 2010-07-22 2012-01-26 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
WO2012011129A3 (en) * 2010-07-22 2012-03-15 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
US8703944B2 (en) * 2010-08-04 2014-04-22 Porton Fine Chemicals Ltd. Method for preparing rosuvastatin calcium intermediate
US20130143908A1 (en) * 2010-08-04 2013-06-06 Porton Fine Chemicals Ltd. Method for preparing rosuvastatin calcium intermediate
WO2012073055A1 (en) 2010-11-29 2012-06-07 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Method for the preparation of high-purity pharmaceutical intermediates
WO2013080219A2 (en) 2011-11-28 2013-06-06 Mylan Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF INTERMEDIATES OF HMG-CoA REDUCTASE INHIBITORS
CN103134893A (en) * 2013-01-25 2013-06-05 峨眉山天梁星制药有限公司 High performance liquid chromatography of 3-tert-butyl dimethyl silica glutaric anhydride
CN103134893B (en) * 2013-01-25 2014-12-03 峨眉山天梁星制药有限公司 High performance liquid chromatography of 3-tert-butyl dimethyl silica glutaric anhydride
CN111548312A (en) * 2020-06-01 2020-08-18 雅本化学股份有限公司 Rosuvastatin calcium tablet and preparation process thereof

Also Published As

Publication number Publication date
EA200401533A1 (en) 2005-06-30
BR0311195A (en) 2005-02-22
EP1585736A2 (en) 2005-10-19
WO2003097614A3 (en) 2004-05-21
AU2003228010A1 (en) 2003-12-02
AR039836A1 (en) 2005-03-02
US20050222415A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
EP1585736A2 (en) Process for the preparation of rosuvastatin
US7566782B2 (en) Process for the preparation of rosuvastatin
EP0520406B1 (en) Diastereomer salt of optically active quinolinemevalonic acid
EP0223334B1 (en) Process for the preparation of aryl-piperidine carbinols
EP2526099B1 (en) Improved process for the preparation of amide intermediates and their use thereof
EP1863773A1 (en) Process for preparation of rosuvastatin
US8212034B2 (en) Process for preparing rosuvastatin calcium
WO2006106526A1 (en) Process for preparation of calcium salt of rosuvastatin
US8394956B2 (en) Process for preparing pyrimidine propenaldehyde
EP2181986A1 (en) Process for the preparation of a precursor of montelukast
WO2008053334A2 (en) An improved process for preparing rosuvastatin calcium
WO2010077062A2 (en) Preparation method of statin compound and benzothiazolyl sulfone compound used therein
US8765947B2 (en) Preparation method of Rosuvastatin calcium and its intermediates
JP4649813B2 (en) Process for producing 2-amino-4- (4-fluorophenyl) -6-alkylpyrimidine-5-carboxylate
WO2008059519A2 (en) A process for the preparation of intermediates of rosuvastatin
US5079382A (en) Process for the production of 3,4-epoxybutyrate and intermediate therefor
WO2006090256A1 (en) Process for the preparation of n-methyl anilino acrolein
CN105566228A (en) Synthetic method of rosuvastatin
US6160115A (en) Process for preparing N-[5-(diphenylphosphinoylmethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin -2-yl]-N-methylmethanesulfonamide
KR20020086718A (en) Process for the selective N-formylation of N-hydroxylamines
JP2003137870A (en) Method for producing 3,5-dioxo-6-heptenoic acid derivatives, and intermediate therefor
CN105461636A (en) Synthetic method for rosuvastatin methyl ester
ZA200206049B (en) Process for the selective N-formylation of N-hydroxylamines.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003725478

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003228010

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3803/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200401533

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 10515361

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003725478

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003725478

Country of ref document: EP